OpenLegislation

Article 17 F1F2

United Kingdom

Original text. Later amendments are not shown.

Whenever, under an agreement between the United Kingdom and a third country, exports are not to be authorised unless an import authorisation has been issued by the competent authorities of that third country F3or the competent authorities of Northern Ireland for the substances in question, the competent authorities in F4Great Britain shall satisfy themselves as to the authenticity of such import authorisation, if necessary by requesting confirmation from the competent authority of the third country or the competent authorities of Northern Ireland.

Annotations

Textual amendments

F1

Regulation revoked (N.I.) (29.6.2026) by The Controlled Drugs (Drug Precursors) (Amendment and Revocation) Regulations 2026 (S.I. 2026/607), reg. 1(1), Sch.

F2

Art. 17 substituted (31.12.2020) by The Law Enforcement and Security (Amendment) (EU Exit) Regulations 2019 (S.I. 2019/742), regs. 1, 14(13); 2020 c. 1, Sch. 5 para. 1(1)

F3

Words in Art. 17 inserted (29.6.2026) by The Controlled Drugs (Drug Precursors) (Amendment and Revocation) Regulations 2026 (S.I. 2026/607), regs. 1(1), 6(14)(a)

F4

Words in Art. 17 substituted (29.6.2026) by The Controlled Drugs (Drug Precursors) (Amendment and Revocation) Regulations 2026 (S.I. 2026/607), regs. 1(1), 6(14)(b)

Notes on the whole EU Regulation

Textual amendments

F2

Substituted by Regulation (EU) No 1259/2013 of the European Parliament and of the Council of 20 November 2013 amending Council Regulation (EC) No 111/2005 laying down rules for the monitoring of trade between the Community and third countries in drug precursors.